QUESTIONS / STATUS DESK
Frequently asked, precisely answered
Twelve concise answers that keep molecule, trial, indication, and approval in the same frame.
What is semaglutide?
Semaglutide is a long-acting analogue of the gut hormone GLP-1. It activates the GLP-1 receptor, strengthening glucose-dependent insulin release, suppressing inappropriate glucagon, slowing gastric emptying, and engaging appetite circuits. In this corpus, its evidence includes randomized weight, cardiovascular, and kidney outcomes [2][3][4]. FDA approval applies to regulated semaglutide products and defined indications; the name alone does not validate unregulated material.
What is semaglutide used for?
The corpus records approved uses spanning type 2 diabetes, chronic weight management, cardiovascular risk reduction in a defined population, and metabolic liver disease. The evidence supporting those areas comes from separate programs. SELECT studied major cardiovascular events in 17,604 adults with established cardiovascular disease and overweight or obesity without diabetes [3]. FLOW studied a kidney-disease composite in 3,533 people with type 2 diabetes and chronic kidney disease [2].
How does semaglutide affect weight?
Semaglutide reduces food intake through GLP-1 receptor signaling in appetite and meal-termination circuits; rodent work maps activity in the hypothalamus, area postrema, brainstem, and parabrachial nucleus [6]. Human effect size comes from trials rather than the animal mechanism. In STEP 1, mean body-weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo [4].
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates both GIP and GLP-1 receptors. A clinical reference identifies it as the first approved dual incretin agonist [8]. The corpus records approved uses for type 2 diabetes, chronic weight management in defined adults, and moderate-to-severe obstructive sleep apnea in adults with obesity. Each use has its own label boundary.
How does tirzepatide compare with semaglutide?
The cleanest answer comes from SURMOUNT-5, a 72-week head-to-head trial of 751 adults with obesity and no type 2 diabetes. Mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide, favoring tirzepatide for that endpoint [1]. The trial does not establish superiority for every clinical outcome or every population.
What safety signal stands out for tirzepatide?
Gastrointestinal effects are the most frequent trial adverse events [10][11]. A meta-analysis of nine randomized trials found an increased composite risk of gallbladder or biliary disease, with relative risk 1.97 and a 95% confidence interval from 1.14 to 3.42. Its pancreatitis estimate was not statistically significant and had a wide confidence interval [9].
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. It activates pituitary GHRH receptors, increasing pulsatile endogenous growth hormone and downstream IGF-1. The United States approval is specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [13]. It is not approved as a general weight-loss or anti-aging treatment.
Does tesamorelin reduce abdominal fat?
Randomized evidence shows reduced visceral fat in adults with HIV-associated lipodystrophy. A meta-analysis of five trials found a pooled reduction of 27.71 square centimeters in visceral adipose area [12], and a smaller randomized trial reported a 42-square-centimeter treatment effect [14]. These figures belong to the studied HIV-associated condition and do not establish a general “belly fat” claim.
What happens after tesamorelin is discontinued?
A 52-week program reported an 18% reduction in visceral fat from baseline during treatment, followed by reaccumulation after discontinuation [16]. That result indicates the observed body-composition effect was not permanent after exposure ended. It also limits any claim that tesamorelin resets visceral-fat biology beyond the treatment period.
What is PT-141?
PT-141 is a development name for bremelanotide, a cyclic peptide agonist of central melanocortin receptors. When discussing approval, the relevant product is bremelanotide injection. Its FDA indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women [21]. The approval does not cover men, postmenopausal women, performance enhancement, or unregulated research-chemical material.
What did the bremelanotide trials find?
Two Phase 3 randomized trials enrolled 1,267 premenopausal women with the defined disorder and reported statistically significant improvements in desire and desire-related distress over 24 weeks [19]. A 52-week open-label extension enrolled 684 women; improvements persisted, and nausea, flushing, and headache were the most common drug-related adverse events [20].
Does FDA approval make every peptide claim reliable?
No. Approval attaches to a defined product, formulation, indication, and population. The same molecule can be approved for one use while other uses remain off-label or investigational. Unregulated material does not inherit the approved product’s manufacturing controls. The status files therefore pair every claim with its study population and endpoint, then state the approval boundary separately.